Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday after Stifel Nicolaus raised their price target on the stock from C$4.15 to C$4.50. The company traded as high as C$4.60 and last traded at C$4.52, with a volume of 77011 shares traded. The stock had previously closed at C$4.47.
MDP has been the topic of several other research reports. Raymond James raised Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 target price on the stock in a research report on Wednesday, January 8th. Alliance Global Partners raised Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday, December 23rd. Finally, Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a research note on Monday, September 30th. Two investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, Medexus Pharmaceuticals presently has a consensus rating of "Strong Buy" and a consensus price target of C$5.58.
Read Our Latest Research Report on MDP
Medexus Pharmaceuticals Stock Performance
The company has a 50 day moving average of C$2.92 and a two-hundred day moving average of C$2.60. The stock has a market capitalization of C$106.21 million, a PE ratio of 86.60 and a beta of 1.96.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Further Reading
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
